For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 51,522 | 38,422 | ||
| General and administrative | 16,537 | 12,472 | ||
| Total operating expenses | 68,059 | 50,894 | ||
| Loss from operations | -68,059 | -50,894 | ||
| Interest income | 8,246 | 8,905 | ||
| Change in fair value of warrant liability | 0 | 106 | ||
| Other expense, net | -165 | -163 | ||
| Total other income, net | 8,081 | 8,636 | ||
| Income (loss) before income taxes | - | -42,258 | ||
| Provision for income taxes | - | 0 | ||
| Net loss | -59,978 | -42,258 | ||
| Unrealized gain on marketable securities | 189 | -37 | ||
| Comprehensive loss | -59,789 | -42,295 | ||
| Basic EPS | -2.17 | -2.18 | ||
| Diluted EPS | -2.17 | -2.18 | ||
| Basic Average Shares | 27,700,855 | 19,352,859 | ||
| Diluted Average Shares | 27,700,855 | 19,352,859 | ||
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)